Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC anti-aging laser

Executive Summary

Palomar Medical Technologies is first company to receive FDA approval for a home-use laser device that treats periorbital wrinkles, the Burlington, Mass. company announces June 5. Developed by Palomar in conjunction with Johnson & Johnson Consumer Companies, the laser is based on years of research and "represents a major breakthrough in the aesthetic device industry," Palomar says. Noting laser treatment for the removal of wrinkles has been proven safe in doctor's offices for years, Palomar CEO Joseph P. Caruso stresses that FDA clearance allows consumers to use the product in their own home "for a fraction of the cost." Palomar is one of a number of companies exploring light-based cosmetic technologies; Home Skinovations recently introduced laser hair removal product Silk'n SensEpil (1"The Rose Sheet" March 30, 2009, p. 6)
Advertisement

Related Content

J&J announces Q3 results
Watch Out, Razors, Here Come Lasers; Skinovations’ Silk’n Rolling Out OTC
Watch Out, Razors, Here Come Lasers; Skinovations’ Silk’n Rolling Out OTC
Advertisement
UsernamePublicRestriction

Register

RS016205

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel